LONQURJA Trademark

Trademark Overview

On Monday, August 25, 2025, a trademark application was filed for LONQURJA with the United States Patent and Trademark Office. The USPTO has given the LONQURJA trademark a serial number of 99356583. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, January 13, 2026. This trademark is owned by Intellia Therapeutics, Inc.. The LONQURJA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations; Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for use with protein disorders and genetic diseases; Intravenous injectable gene therapy preparations for treating and managing swelling attacks; Therapeutic agents in the nature of CRISPR/Cas9 protein with guide RNAs targeting the KLKB1 gene to reduce production of plasma prekallikrein and control bradykinin generation
lonqurja

General Information

Serial Number99356583
Word MarkLONQURJA
Filing DateMonday, August 25, 2025
Status641 - NON-FINAL ACTION - MAILED
Status DateTuesday, January 13, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical and biological preparations; Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for use with protein disorders and genetic diseases; Intravenous injectable gene therapy preparations for treating and managing swelling attacks; Therapeutic agents in the nature of CRISPR/Cas9 protein with guide RNAs targeting the KLKB1 gene to reduce production of plasma prekallikrein and control bradykinin generation

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 25, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameIntellia Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, August 25, 2025NEW APPLICATION ENTERED
Monday, August 25, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 25, 2025APPLICATION FILING RECEIPT MAILED
Friday, January 9, 2026ASSIGNED TO EXAMINER
Tuesday, January 13, 2026NON-FINAL ACTION WRITTEN
Tuesday, January 13, 2026NON-FINAL ACTION E-MAILED
Tuesday, January 13, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords

lonqurja preparations pharmaceutical gene biological treating angioedema protein hereditary managing klkb